Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
2
67%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

unknown267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_2

Strategy for Improving Stroke Treatment Response

NCT05948566
unknownphase_2

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

NCT05408546
unknownphase_1

Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer

NCT03001544

Clinical Trials (3)

Showing 3 of 3 trials
NCT05948566Phase 2

Strategy for Improving Stroke Treatment Response

Recruiting
NCT05408546Phase 2

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

Unknown
NCT03001544Phase 1

Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3